Skip to content

Information about how we use cookies

This website uses cookies to provide you with the best possible experience of the website. By continuing to use the website, you agree to our use of cookies. More information about our privacy policy and how we handle cookies can be found here

Help links

  • Sitemap
  • Choose country
    • Swedish
    • Norwegian
    • Danish
    • Finnish
    • Dutch
Navamedic Navamedic

Main navigation

  • Portfolio
  • Investor relations
  • Newsroom
  • About Navamedic
  • Contact
Search

Newsroom

  • 2019
  • 2018
  • 2017
    • December
    • November
    • August
    • July
    • June
    • May
    • April
    • March
    • February
    • January
  • 2016

March

  • 2017-03-01

    Navamedic extends distribution of Imdur to four new European markets

    Oslo, 1 March 2017 – Navamedic ASA (OSE: NAVA),
    the Norwegian medtech and pharmaceutical products company, today announced it is expanding distribution of the angina prevention medicine, Imdur®, to the United Kingdom, Ireland, Malta and Cyprus during the month of March, bringing the distribution to a total of thirteen markets across Europe.
    Imdur® is part of a strategic partnership with TopRidge
    Pharma Limited (TopRidge Pharma), under which the product has
    become Navamedic’s largest single brand.

    
            
Top

Navamedic ASA

Fornebuveien 42-44 P.O. Box 107 N-1325 Lysaker Norway

Privacy Policy

Investor relations

  • The Share
  • Annual Reports
  • Quarterly Reports
  • IFRS
  • Presentations
  • Corporate Governance
  • Financial Calendar
  • IR Contacts
  • Product Launches

About Navamedic

  • Management
  • Board of Directors
  • Company History
  • Careers
  • Our Partners
  • Business Development
  • Privacy Policy

Copyright © 2016 Navamedic ASA Sitemap Contact

  • Facebook